Interleukin-1 receptor associated kinase 1 (IRAK1) is epigenetically activated in luminal epithelial cells in prostate cancer.
DNA methylation
IRAK1
Myddosome complex
epigenetic regulation
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
07
2022
accepted:
01
09
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
The use of immune adjuvants such as toll-like receptor (TLR) agonists reflects a novel strategy in prostate cancer (PCa) therapy. However, interleukin-1 receptor associated kinase 1 (IRAK1), a central effector of TLR signaling, has been shown to be responsible for resistance to radiation-induced tumor cell death. In order to better understand the function and epigenetic regulation of IRAK1 in PCa, we performed
Identifiants
pubmed: 36226067
doi: 10.3389/fonc.2022.991368
pmc: PMC9549294
doi:
Types de publication
Journal Article
Langues
eng
Pagination
991368Informations de copyright
Copyright © 2022 Schagdarsurengin, Breiding, Loose, Wagenlehner and Dansranjav.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Oncol. 2020 Oct 09;10:580617
pubmed: 33163409
J Exp Med. 2005 Mar 21;201(6):915-23
pubmed: 15767370
Cancer Immunol Immunother. 2011 Feb;60(2):217-26
pubmed: 20978888
J Biol Chem. 2002 Mar 1;277(9):7059-65
pubmed: 11751856
J Cell Biochem. 2018 Mar;119(3):2545-2555
pubmed: 28980703
Oncogene. 2008 Sep 18;27(42):5643-7
pubmed: 18504431
J Immunol. 2002 Dec 15;169(12):6668-72
pubmed: 12471095
Bioinformatics. 2014 Feb 01;30(3):428-30
pubmed: 24336642
Immunobiology. 2017 Jan;222(1):89-100
pubmed: 27349597
Onco Targets Ther. 2017 Mar 21;10:1711-1723
pubmed: 28356759
Cell Rep. 2018 Dec 18;25(12):3530-3542.e5
pubmed: 30566875
Cell. 2013 Dec 19;155(7):1521-31
pubmed: 24360275
Oncotarget. 2015 Dec 22;6(41):43395-407
pubmed: 26527316
Nat Cell Biol. 2019 Feb;21(2):203-213
pubmed: 30664786
Immunopharmacology. 2000 Sep;49(3):241-6
pubmed: 10996021
Mol Cell. 2016 May 5;62(3):422-431
pubmed: 27153539
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Commun. 2015 Oct 27;6:8746
pubmed: 26503059
J Exp Pharmacol. 2016 Aug 16;8:11-9
pubmed: 27574472
Prostate. 2008 Feb 1;68(2):223-9
pubmed: 18092352
Front Public Health. 2022 Feb 16;10:811044
pubmed: 35252092
Front Immunol. 2014 Jul 31;5:367
pubmed: 25132836
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Adv Exp Med Biol. 2019;1210:409-436
pubmed: 31900919
Mol Cell Biol. 1999 Jul;19(7):4643-52
pubmed: 10373513
Oncotarget. 2018 Sep 7;9(70):33416-33439
pubmed: 30279971
Nat Commun. 2022 Jan 10;13(1):141
pubmed: 35013146
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
ACS Med Chem Lett. 2020 Oct 09;11(11):2238-2243
pubmed: 33214835
Int J Mol Cell Med. 2019 Summer;8(3):200-209
pubmed: 32489949
J Cell Mol Med. 2020 Jul;24(14):8006-8017
pubmed: 32485038
J Immunol. 1999 Jul 15;163(2):978-84
pubmed: 10395695
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Int J Mol Sci. 2021 Feb 09;22(4):
pubmed: 33572095
J Biol Chem. 2001 Aug 3;276(31):29037-44
pubmed: 11397809
Cancer Metastasis Rev. 2002;21(1):3-16
pubmed: 12400993
Clin Cancer Res. 2010 Jan 1;16(1):34-44
pubmed: 20028769
FEBS Lett. 2003 Jul 17;547(1-3):157-61
pubmed: 12860405
Oncogene. 2008 Jan 7;27(2):200-7
pubmed: 18176601
Oncotarget. 2015 Apr 30;6(12):9897-907
pubmed: 25846753
Urology. 2002 Jul;60(1):78-83
pubmed: 12100928
Int Immunopharmacol. 2022 Jun;107:108708
pubmed: 35306281
J Exp Clin Cancer Res. 2016 Sep 13;35(1):140
pubmed: 27619757
Cancer Cell. 2012 Oct 16;22(4):466-78
pubmed: 23079657
Tumour Biol. 2014 Oct;35(10):9627-37
pubmed: 24964964
J Cell Mol Med. 2013 Jun;17(6):713-22
pubmed: 23551576
Bioinformatics. 2021 Jan 18;:
pubmed: 33459785
Cancer Res. 2021 Mar 1;81(5):1413-1425
pubmed: 33402387